FV-100 治疗水痘-带状疱疹病毒（VZV）感染：路在何方？

Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.

Viruses. 2022 Apr 7;14(4):770. doi: 10.3390/v14040770.

The bicyclic nucleoside analogue (BCNA) Cf1743 and its orally bioavailable prodrug FV-100 have unique potential as varicella-zoster virus (VZV) inhibitors to treat herpes zoster (shingles) and the therewith associated pain, including post-herpetic neuralgia (PHN). The anti-VZV activity of Cf1743 depends on a specific phosphorylation by the VZV-encoded thymidine kinase (TK). The target of antiviral action is assumed to be the viral DNA polymerase (or DNA synthesis in the virus-infected cells).

双环核苷类似物（BCNA）Cf1743 及其口服生物利用前药 FV-100 具有作为水痘带状疱疹病毒（VZV）抑制剂的独特潜力，可用于治疗带状疱疹（带状疱疹）及其相关疼痛，包括带状疱疹后神经痛（PHN）。Cf1743 的抗 VZV 活性取决于 VZV 编码的胸苷激酶（TK）的特异性磷酸化。抗病毒作用的靶标被认为是病毒 DNA 聚合酶（或病毒感染细胞中的 DNA 合成）。